Clinical Trial Update: Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of rituximab and interleukin-2 in patients with relapsed or refractory intermediate- or high-grade non-Hodgkin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Rituximab (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED